Introduction
Primary central nervous system (CNS) malignancies continue to have a high mortality. Approximately one-half of these cases are malignant gliomas which are classified as glioblastoma multiforme (Kernohan' s grade IV) and anaplastic astrocytoma (Kernohan's grade III) [1] . Malignant gliomas are uniformly fatal tumors. Studies by the Brain Tumor Study Group [2] have shown a median survival of 17 weeks in patients who have received only surgical resection. Survival was extended to a median of 37 weeks with radiation therapy (RT). The additional of singleagent chemotherapy has improved long term survival to a limited extent. BCNU, when used after resection and RT, improved the median survival to 51 weeks [3] in one trial and 50 weeks in another [4] .
In recent years newer methods of administration have been sought. Craft et al. [5] compared 14C-labelled BCNU given IV and IA in monkeys and found IA administration produced a four-fold higher brain drug level than IV administration of the same dose. These and subsequent studies suggested that IA administration could potentially reduce systemic toxicity [6] . Cisplatin (cisdichlorodiammineplatinum; DDP) is an inorganic complex formed by an atom of platinum (II) surrounded by chlorine and ammonia atoms in the cis position of the horizontal plane. DDP has antitumor effect in a wide variety of neoplasms, especially testicular [7] , bladder [8] , ovarian [9] , and head and neck tumors [10] . The mode of action of DDP appears to be direct binding to DNA, forming intrastrand and interstrand cross links between guanine residues [11] .
DDP has also been shown to be effective against primary CNS malignancies. Initial studies by Kahn et al. [12] and Levanthal and Freeman [13] using IV DDP were encouraging. Stewart et al. [14] studied IA administration of DDP in patients with glioblastoma multiforme and metastatic tumors. Six of their 10 evaluable patients responded to treatment. They were able to demonstrate that IA infusion of DDP (60 mg/m 2 q6 wks) via transfemoral selective inter-al carotid artery catheterization was technically feasible and capable of producing tumor regression or stabilization. Subsequent studies using IA DDP have also shown encouraging results against primary CNS tumors [15] [16] [17] [18] . This report describes our experienc using IA DDP in the treatment of patients with malignant gliomas.
Materials and methods
Twelve patients were entered into the study. Patient characteristics are listed in Table 1 . Prior to entry all patients had had at least one subtotal resection, and all had pathological confirmation of their diagnosis. Nine patients had glioblastoma multiforme or anaplastic astrocytoma (grade III or IV astrocytoma). The remaining patients had gliosarcoma, grade II/II1 astrocytoma/oligodendroglioma, and ependymoma, respectively. These tumors were all unilateral and confined to the left or right internal carotid arterial distribution. The average age was 43 years with a range of 11-62 years. All patients had received between 5400-6600 rads of radiation prior to this study. Eleven of 12 patients had received prior chemotherapy. All 11 had received IA BCNU. Two had received continuous infusion of IA dichloromethotrexate (DCMTX). One each had received IA diaziquone (AZQ), continuous IA flourodeoxyuridine (FUdR), and IV dacarbazine (DTIC). One patient also received vincristine and procarbazine. Nine of the 12 patients were taking stable doses of During treatment each patient had weekly CBC with differential and platelet counts. Bimonthly each patient received a neurologic examination and Karnofsky rating. Audiograms were repeated every 12 weeks. The pretreatment laboratory battery was repeated prior to each subsequent treatment.
Prior to administration of IA DDP, each patient received hydration with D5 0.45% NaCL at 150 cc/hr for 12 hours. Dexamethasone 50 mg IV was given the night before DDP adminstration. It was repeated along with mannitol 12.5 Gm IV the morning of DDP administration. DDP (Bristol Laboratories) was dispensed for IA use in the form of lyophilized powder in 10 mg vials. It was reconstituted for IA use by dissolving 58-100 mg/m 2 in 175 to 200 ml of 0.45% NaCL solution. Heparin (1000 units) was added to each infusion. The DDP was infused into the left or right internal carotid artery via a catheter placed percutaneously using the femoral approach (10 patients) or through the sideport of an Infusaid permanently implantable intracarotid drug delivery system (manufactured by Shiley Infusaid Corp., Norwood, MA) (2 patients). The Infusaid pump had been implanted prior to entry this study using a technique described by Phillips etal. [19] . An IMED 960 (Medical electronics Corp.) infusion pump was used to infuse DDP through the catheter over one hour. A hyperalimentation filter was in place between the DDP solution and the femoral catheter. In all infusions, the catheter was below the ophthalmic artery. After infusion, each patient was hydrated with D5 0.45% NaCL at 200 cc/hr for 12 hours. Urine output was monitored closely. If it dropped below 200 cc/hr, mannitol 12.5 Gm IV was given. Metoclopramide and lorazepam were administered as needed for nausea and vomiting. Treatment was repeated at 4-6 week intervals as long as the patient remained stable or improved and had absolute granulocyte counts greater than 2500 and platelet counts greater than 100000.
Response criteria were as follows: Complete Response -complete resolution of all abnormalities on CT scan and an improved or normal neurologic examination without steroid medication; Partial Response -a decrease in the size of the measurable mass lesion on CT scan plus a stable or improved neurologic examination on stable or decreasing doses of steroids; Stable Disease -no change in the size of the tumor on CT scan without significant change in neurologic examination on stable or decreasing doses of steroids; Progressive Diseaseincrease in the size of the tumor on CT scan and/or progressive worsening of neurologic function directly attributable to the growth effects of the tumor. The duration of response dated from the onset of treatment until demonstration of disease progression. A complete trial consisted of at least two infusions of DDR The trial was stopped after one infusion if a patient demonstrated unequivocal progression.
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Results
Twelve patients received a total of 24 IA DDP infusions. Patient response characteristics are listed in Table 2 . Eighteen of 24 infusions were at a dosage of 75 mg/m 2. Other doses were as follows: one at 58 mg/m 2, three at 90mg/m 2, and two at 100 mg/m 2. Five patients received one course of DDP, four patients received two courses, two patients received three courses, and one patient received five courses o f DDP. The cumulative dosage ranged from 140 to 580 mg, with an average of 266 mg.
Only one of 12 patients (8°70) demonstrated a response to IA DDP. There were no complete responders. Patient #3 who had a left frontoparietal grade II-III astrocytoma/oligodendroglioma, and had not responded to prior BCNU, had a partial response for six months during which time she received three more treatments. After her second treatment with DDP her tumor displayed diminished bulk and mass effect by CT. During that time she was clinically stable. Repeat CT scan subsequently showed slightly increased volume and enhancement. Ten of the remaining 11 patients had progressive disease. Five patients demonstrated both CT and clinical progression. Four patients had stable CT examination but progressed clinically. Clinical progression was manifested by worsening mono- P S P 4 P P P 4 P P P 3 P P S 1.5 P P P 1.5 P P S 3 P P P 1
Abbreviations: R -partial response; S -stable; P -progression; C -complications or hemiparesis in five patients, progressive aphasia in six patients, increased seizure frequency in two patients, and progressive headache in two patients. One patient had a stable clinical exam but had CT progression. The last patient's (patient #12) tumor was stable by CT criteria but developed complications from the DDP infusion including mental status changes and encephalopathy that progressed to coma. The range of time to treatment failure was one to six months. The average time to treatment failure was 3.0 months. Toxicity data are listed in Table 3 . The most frequent acute toxicity was gastrointestinal. Seven of our twelve patients developed symptoms of nausea and vomiting. These symptoms were transient, clearing after 24 hours, although they did require treatment with antiemetics. Three patients experienced mild myelosuppression with WBC reaching nadirs of 2500, 2500, and 2400, respectively. All platelet count nadirs remained above 125000. None of our patients developed renal toxicity, hypomagnesemia or diminished auditory acuity.
Two patients exhibited retinal toxicity with associated decreased visual acuity of the ipsilateral eye. Patient #1 complained of pain in his left eye during and after his initial DDP infusion. He subsequently lost visual acuity and became blind in that eye. Ophthalmic examination and fluorescein angiography revealed retinal vasculitis. Patient #3 had no pain during DDP infusion but developed blurred vision and diminished visual acuity after her second treatment.
The remaining toxicity was referable to the CNS. Three patients had acute seizure activity during infusion of DDP. Patients #6 and 10 exhibited brief spontaneously resolving simple partial seizures of the arm, and arm and leg, respectively, contralateral to the side of infusion. Patient #2 developed status epilepticus which progressed to an encephalopathic and then comatose state. She died four weeks after her initial infusion. CT scans during this time were unchanged.
Four patients developed weakness and/or aphasia. Patient #3 acutely developed expressive aphasia after her second infusion which never completely resolved. Patient #6 developed an acute complex of signs three days after treatment that included increased hemiparesis, seizure activity, and aphasia. He progressed to an encephalopathic state, followed by coma, which lasted for two weeks. He eventually recovered alertness but was left with a dense right hemiparesis and severe expressive aphasia. Patient #9 acutely developed aphasia and right arm weakness that resolved after 12 hours. Patient #10 acutely developed right hemiparesis that never returned to baseline after months of follow-up. One patient developed trigeminal mononeuropathy manifested by numbness of the face ipsilateral to the side of her infusion. This developed after her fourth treatment. 
Discussion
The theoretical advantages of administering a chemotherapeutic agent IA instead of IV have been examined by previous authors [6, 20] . The regional advantage R d is defined as the ratio of tumor exposure with IA administration to that with IV administration, where exposure is the concentrationtime integral. Assuming linear kinetics of drug distribution and metabolism it can be shown that Rd is independent of the rate of drug administration. Assuming clearance by the lungs is negligible:
where F is flow in the artery infused (L/min), and CL(tb) is the total body metabolic clearance of the drug (L/min) [20] . It is apparent from this relationship that R a for a given drug can be maximized by low flow in the artery infused and by rapid systemic clearance of the drug. Ra for BCNU has been measured in squirrel monkeys [21] . IA administration increased the total tissue radioactivity by 2. show a total body clearance rate for DDP of approximately 0.365 L/min. If unilateral internal carotid artery blood flow is estimated to be 0.25 L/rain, then R d is calculated to be 2.46. Based on this information, an advantage for IA therapy was postulated and formed the rationale for administering DDP IA in our study. A recent study using positron emission tomography (PET) analysis of DDP adminstration estimated R a to be 2.5 [23] . This measured value closely approximates our calculated value of Rd.
In our study, none of our patients had a complete response. One of 12 had a brief partial response. She had a grade II-III astrocytoma/oligodendroglioma. Recent data from Cairncross and Macdonald [24] suggests that oligodendrogliomas are quite chemosensitive. Her partial response may have been from this fraction of tumor. The efficacy of IA DDP was less than that seen in most other trials of IV [12, 13] or IA [14] [15] [16] [17] [18] administered DDP. Our response rate was also considerably less than those obtained with IV BCNU [3, 4] . Possible explanations for our low response rate may be related to the fact that in our study 92% of our patients had failed IA BCNU therapy. A higher percentage of our patients failed previously chemotherapy than in other studies. The BCNU may have selectively killed clones of cells that would have been sensitive to DDP, allowing repopulation with more resistant cells [25, 26] . In vitro studies comparing cross-resistance between alkylating agents showed significant cross-resistance between BCNU and DDP [27] . It is therefore possible that IA DDP would be more efficacious when used 43 with patients who have not received prior IA BCNU chemotherapy. Ongoing research at our institution does suggest that procarbazine may be an effective agent when used to treat patients after failure of IA BCNU (unpublished data). A further possible explanation for our lack of partial responders may be that our treatment interval was too long. By using shorter intervals, more partial responses may have been seen, but this probably would have resulted in further toxicity. The high pre-treatment doses of dexamethasone used theoretically could have affected the blood-brain barrier and decreased the amount of DDP delivered to the tumor. High pre-treatment doses of dexamethasone could have also increased tumor concentrations of metallothionein (MT), an inducible low molecular weight protein that binds heavy metal compounds, including platinum, and affords resistance to DDP [28, 29] . However, recent in vitro data in rat hepatocytes showed that after initial MT induction by steroids, further increments in dosage or length of treatment did not significantly increase MT concentrations [28] . Therefore, since our patients were on chronic doses of dexamethasone, the effects of additional steroid on MT induction were probably negligible.
We doubt that our response rates were compromised because of the DDP doses administered. Data from several studies showed that at least 60 mg/m 2 of IA DDP was adequate to achieve a response [14] [15] [16] . All but one of our patients received 75-100 mg/m 2 of DDP per dose.
An additional patient not included in our study with metastatic squamous cell carcinoma to the base of skull and parasellar region was an unequivocal responder. She received six treatments with IA DDP at a dose of 75 mg/m 2. Clinically she remained stable while CT scan showed shrinkage of her tumor. This partial response lasted for seven months. She then developed increased tumor mass by CT.
The major dose limiting toxicity in our study was neurotoxicity. None of our patients developed severe toxicity of the GI tract, kidneys, or bone marrow. Four of our patients experienced acute seizure activity, one of whom had status epilepticus requiring treatment. Seizures have been reported by other authors, but not as frequently as in our series [15, 30] . Three patients experienced increased mono-or hemiparesis. All had large tumors with significant enhancement and surrounding edema. Kapp and Sanford [31] theorize that gliomas, especially if near the internal capsule, could disrupt relatively the blood-brain barrier of nearby normal neural tissue exposing it to toxic concentrations of DDP that could produce dysfunction. Our patients received aggressive post-treatment hydration which could have lead to an exacerbation of vasogenic edema to an already disrupted blood-brain barrier. An alternative explanation is that these acute infusionrelated complications represented thromboembolic events. Two patients each developed encephalopathy progressing to coma. This has also been documented by Feun et al. [15] . One of these patients remained in coma until death while the other recovered after two weeks. The etiology of these catastrophic events and why it affected these patients in a differential fashion is unclear.
To further clarify the CNS toxicity seen in our patients, the role of prior BCNU was evaluated. The patients who had received prior BCNU and did not develop complications had a mean total dose of 981 mg/m 2. The mean total dosage in patients who did develop complications was 1066 mg/m 2. This is not a significant difference and does not support a correlation between prior BCNU dosage and subsequent development of complications with IA DDP.
A major dose-limiting toxicity in many studies has been retinal toxicity [15, 32] . In this study, one patient developed a painless decrement in visual acuity after her second treatment. A second patient developed pain and blurring of vision coincident with his initial DDP infusion that progressed to complete blindness. Recent attempts to avoid retinal toxicity by using supraophthalmic infusion techniques although initially promising, may increase CNS toxicity [17, 33] .
Ototoxicity has been a frequent complication of therapy in some studies [34, 35] . None of our patients developed ototoxicity. An additional patient with metastatic squamous cell carcinoma, not included in this study, received IA DDP divided between the left carotid and vertebral arteries and developed moderately severe ototoxicity after her fifth treatment. It appears that the large cumulative doses of DDP, as well as infusion of the drug via the posterior circulation, made this patient more vulnerable to ototoxicity. This patient also developed peripheral neuropathy as a consequence of DDP. She received cumulative DDP doses in excess of 375 mg/m 2. Thompson et al. [36] have reported that peripheral neuropathy becomes clinically apparent after a cumulative DDP dose of 350 mg/m 2. Our study corroborates their threshold dose. Although it is not clear whether the same mechanism is involved, our glioma patient with trigeminal mononeuropathy also had a cumulative DDP dose in excess of 350 mg/m 2. All other patients had cumulative doses less than 280 mg/m 2 and did not develop peripheral neuropathy.
Conclusion
IA administration of DDP has very limited efficacy in patients with primary malignant gliomas showing disease progression after proving refractory to nitrosourea therapy. In our study, only one of 12 patients responded to IA DDP treatment. The DDP doses used in our study of 75 mg/m 2 or more resulted in an unacceptable level of toxicity, especially to the CNS. However, DDP may prove to be more effective when used as initial therapy.
